pre-miRNA Information | |
---|---|
pre-miRNA | hsa-let-7a-1 |
Genomic Coordinates | chr9: 94175957 - 94176036 |
Synonyms | LET7A1, MIRNLET7A1, let-7a-1, MIRLET7A1 |
Description | Homo sapiens let-7a-1 stem-loop |
Comment | let-7a-3p cloned in has a 1 nt 3' extension (U), which is incompatible with the genome sequence. |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-let-7a-3 |
Genomic Coordinates | chr22: 46112749 - 46112822 |
Synonyms | LET7A3, MIRNLET7A3, let-7a-3, MIRLET7A3 |
Description | Homo sapiens let-7a-3 stem-loop |
Comment | let-7a-3p cloned in has a 1 nt 3' extension (U), which is incompatible with the genome sequence. |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-let-7a-3p | |||||||||||||||||||||||||||||||||||||||
Sequence | 57| CUAUACAAUCUACUGUCUUUC |77 | |||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SHOC2 | ||||||||||||||||||||
Synonyms | SIAA0862, SOC2, SUR8 | ||||||||||||||||||||
Description | SHOC2, leucine rich repeat scaffold protein | ||||||||||||||||||||
Transcript | NM_007373 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SHOC2 | |||||||||||||||||||||
3'UTR of SHOC2 (miRNA target sites are highlighted) |
>SHOC2|NM_007373|3'UTR 1 TATAAATCTGCTGGTCCCACACACTGTTCAAAAATAGACTGCCATTAATGTTTCTTATCTATATCTGTATCTATTTATGT 81 AGATATTGGTATATGGCAGATTTATAAAAATTGCATTATGTGTTTCTGCTAATAGAGGAATCATAGCCATTTAGAATTTT 161 TTTTAAATTCTGTACAAAAGGCTTATATAAGTTTTCTTTGCTGAATTTGATGGATGTTTTTCTGTTGTGTAATCTGATAT 241 GCCAGTTTGCTTAAAACATTTGCCAACACATTATGAAGTTATTAAATTTAAGGGACAGAGGTAGTATAGTTAGATATACT 321 TTCTCTTAGGAAAAATAATGGGCAAAAATTTTTGTTGCAACTTTTCATATATATTTTCCCCTTACCAATTGTTTTATCCT 401 TATAGTATTGTAGGCCCTGAAAGTAGAATTTTTCTTTAACTTATTTTGAGATTTGAGATTTAAATTTTATGTATTGTTTA 481 CAGTCAGAGTAAATCACTGGATTTCTTTTGTTTGTTTTGATTTGCTCTGTTTTATTCAGTCAAATCTAGAGTTTGAATCC 561 TCTGCTAAAGAATTTGCATCCACTGGTGTAAACAGTGAAAGGTATTTGCTTGTTGAAAAAAAAAACTGGCAAAGTGAAAA 641 GATACAGTCAAAAATCTAGAATTTCTTTAATTTTGCTTCTCTGACGAGTTGTGAAGCAAAATACCTGAAGTGAGTCTTTG 721 GGTAGGGGAAGGGTATTGAGACCTTTTCTAGTATGAATATTTTTTAAGTTTGGGGGAAGAGAAACTTGCAGTGAAAAGGA 801 GTTTTTTCATTCCTGAAAGTTGCAGATCCACAAAACTAACAGGATAATTGGGCAAATAAATTACATATAAACACACACAA 881 TCTATATATGTATATACAATGCTATATAGATATGTATTTATTATATCATAAACTACAGTAGGTAACTTTAAGGATTTCTT 961 CCTATCCTTGTACAATGACATGAATGTCTTTCTTTGAAAACTGCAATGTATGTATGTTTCAAGGTTATTTAACAGTGTAC 1041 TATGGTTTTATATCTTGACTTGCCTTGTACATCTTTCAATTCTGGAATATCTGTGTCTAAGCACAATATCTTCACACTGT 1121 GCTGTATTGCTGCTGAACTAAATGCACTTTTCCCCACATATGGGGCACTGGCTTCAAACAATTCAGTTCAGTATCATTAC 1201 TTTTAATCTCATCTTTCCTTTCTTGGTAGTTGTTAATACAGTTATGGAAAAGAGGCACATTGCATAGAAGCCATTGGGGA 1281 GTTCAGTGGAAGTTCTGTAAGATGTGCATGTACTATTTGATGCGTTTTCTTTGCTTCACTGCTTTTAATACTTAGCAGTA 1361 TTGTTGGTCTAAGTCAATTTGATTATTGAGGAGTCTCAGAGCAAGGTGCGTTCTAGATGTCATCCTAAAAAACACTTCAT 1441 ATATAATTAATCACTATTTTGTATAATTACATATTGCTGCTTGTGTGTTTTTTTTTTTTTCCATTTAGTTGGGCGTTGTG 1521 TTTTACACAAAACCATTTTTGAATTAAGGCTATGATATTAAGATAGAAATTTGGACTGTTGTTCTGCTTTTCCTGGCACT 1601 CAAATTCATGACTAGTTTTGAGGTCAAACCTATGTTCGTAATGAGAGATTTTATAAGGATCAACTAAGAAATGGAAGGCA 1681 GGTGAAGATATAAAACCCTAGAATGCTTAAATGTGCTGTAAAACTATTGTAGATGTCACTGGATTTTACCAAGTAATATC 1761 CTTTCTTTTTTTTTTCCCCCCATCTGCTGTGGCTTTTCAGTTAAAATTTTGTTTATAAAAGGAATTTGTTTATTACAGCT 1841 CTACCTAGAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545212. RNA binding protein: AGO1. Condition:Control
PAR-CLIP data was present in GSM545214. RNA binding protein: AGO3. Condition:Control
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
PAR-CLIP data was present in GSM545217. RNA binding protein: AGO2. Condition:miR-7 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 8036.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 8036.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065667. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065668. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065669. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065670. RNA binding protein: AGO2. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 5 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | MCF7 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset GSM545212 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000369452.4 | 3UTR | GUAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545214 | |
---|---|
Method / RBP | PAR-CLIP / AGO3 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000369452.4 | 3UTR | AUCACUAUUUUGUAUAAUUACAUAUUGCUGCUUGUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM545217 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-7 transfection |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM1065667 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_6 |
Location of target site | ENST00000369452.4 | 3UTR | GUAUAAUUACAUAUUGCUGCUUGUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset GSM1065668 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_7 |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 8 for dataset GSM1065669 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_8 |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 9 for dataset GSM1065670 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / 4-thiouridine, 3_ML_LG |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 10 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
CLIP-seq Support 11 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000369452.4 | 3UTR | UAUAAUUACAUAUUGCUGCUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
121 hsa-let-7a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT038998 | ARMC8 | armadillo repeat containing 8 | 1 | 1 | ||||||||
MIRT038999 | SETD4 | SET domain containing 4 | 1 | 1 | ||||||||
MIRT039000 | BTF3 | basic transcription factor 3 | 1 | 1 | ||||||||
MIRT039001 | MIPOL1 | mirror-image polydactyly 1 | 1 | 1 | ||||||||
MIRT039002 | TRIM33 | tripartite motif containing 33 | 1 | 1 | ||||||||
MIRT039003 | CS | citrate synthase | 1 | 1 | ||||||||
MIRT039004 | SENP7 | SUMO1/sentrin specific peptidase 7 | 1 | 1 | ||||||||
MIRT055418 | SHOC2 | SHOC2, leucine rich repeat scaffold protein | 2 | 10 | ||||||||
MIRT057681 | LCOR | ligand dependent nuclear receptor corepressor | 2 | 8 | ||||||||
MIRT061351 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 2 | ||||||||
MIRT062174 | WNK1 | WNK lysine deficient protein kinase 1 | 2 | 2 | ||||||||
MIRT071813 | RNF11 | ring finger protein 11 | 2 | 2 | ||||||||
MIRT091374 | EIF4A2 | eukaryotic translation initiation factor 4A2 | 2 | 2 | ||||||||
MIRT095107 | SEC24A | SEC24 homolog A, COPII coat complex component | 2 | 2 | ||||||||
MIRT098814 | PPIL4 | peptidylprolyl isomerase like 4 | 2 | 2 | ||||||||
MIRT109534 | KLHL15 | kelch like family member 15 | 2 | 4 | ||||||||
MIRT120263 | GSK3B | glycogen synthase kinase 3 beta | 2 | 2 | ||||||||
MIRT149839 | LDLR | low density lipoprotein receptor | 2 | 6 | ||||||||
MIRT164519 | MSMO1 | methylsterol monooxygenase 1 | 2 | 2 | ||||||||
MIRT165879 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT169899 | HBP1 | HMG-box transcription factor 1 | 2 | 4 | ||||||||
MIRT182779 | TOR1AIP2 | torsin 1A interacting protein 2 | 2 | 2 | ||||||||
MIRT193466 | RORA | RAR related orphan receptor A | 2 | 2 | ||||||||
MIRT226421 | TP53INP1 | tumor protein p53 inducible nuclear protein 1 | 2 | 2 | ||||||||
MIRT334410 | CREBZF | CREB/ATF bZIP transcription factor | 2 | 6 | ||||||||
MIRT338286 | SYF2 | SYF2 pre-mRNA splicing factor | 2 | 2 | ||||||||
MIRT361627 | TES | testin LIM domain protein | 2 | 2 | ||||||||
MIRT406687 | ZNF181 | zinc finger protein 181 | 2 | 2 | ||||||||
MIRT407768 | MRPL35 | mitochondrial ribosomal protein L35 | 2 | 2 | ||||||||
MIRT449468 | HAT1 | histone acetyltransferase 1 | 2 | 2 | ||||||||
MIRT467110 | SRI | sorcin | 2 | 2 | ||||||||
MIRT475099 | IRF2BP2 | interferon regulatory factor 2 binding protein 2 | 2 | 6 | ||||||||
MIRT481671 | ARAP2 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 | 2 | 2 | ||||||||
MIRT493061 | MTFR1 | mitochondrial fission regulator 1 | 2 | 2 | ||||||||
MIRT497923 | BTG1 | BTG anti-proliferation factor 1 | 2 | 2 | ||||||||
MIRT498202 | ACVR2B | activin A receptor type 2B | 2 | 2 | ||||||||
MIRT503391 | ASB11 | ankyrin repeat and SOCS box containing 11 | 2 | 6 | ||||||||
MIRT503862 | UBXN2B | UBX domain protein 2B | 2 | 2 | ||||||||
MIRT504368 | ARID1B | AT-rich interaction domain 1B | 2 | 4 | ||||||||
MIRT504991 | ZNF652 | zinc finger protein 652 | 2 | 2 | ||||||||
MIRT505754 | SENP1 | SUMO1/sentrin specific peptidase 1 | 2 | 8 | ||||||||
MIRT518102 | ADH1B | alcohol dehydrogenase 1B (class I), beta polypeptide | 2 | 6 | ||||||||
MIRT521930 | PHF8 | PHD finger protein 8 | 2 | 4 | ||||||||
MIRT522139 | NRBF2 | nuclear receptor binding factor 2 | 2 | 6 | ||||||||
MIRT522401 | MYADM | myeloid associated differentiation marker | 2 | 4 | ||||||||
MIRT523593 | FZD5 | frizzled class receptor 5 | 2 | 4 | ||||||||
MIRT523944 | E2F8 | E2F transcription factor 8 | 2 | 4 | ||||||||
MIRT524355 | CREB1 | cAMP responsive element binding protein 1 | 2 | 2 | ||||||||
MIRT525140 | ZNF256 | zinc finger protein 256 | 2 | 2 | ||||||||
MIRT527070 | ABCC4 | ATP binding cassette subfamily C member 4 | 2 | 2 | ||||||||
MIRT527486 | OCIAD1 | OCIA domain containing 1 | 2 | 2 | ||||||||
MIRT528129 | PPP1R10 | protein phosphatase 1 regulatory subunit 10 | 2 | 2 | ||||||||
MIRT530528 | ALG10B | ALG10B, alpha-1,2-glucosyltransferase | 2 | 2 | ||||||||
MIRT531270 | PPIL3 | peptidylprolyl isomerase like 3 | 2 | 2 | ||||||||
MIRT538898 | BRI3BP | BRI3 binding protein | 2 | 2 | ||||||||
MIRT541371 | CDKN1B | cyclin dependent kinase inhibitor 1B | 2 | 2 | ||||||||
MIRT541526 | MGAT4C | MGAT4 family member C | 2 | 2 | ||||||||
MIRT543776 | RBM12B | RNA binding motif protein 12B | 2 | 4 | ||||||||
MIRT543946 | NCOA7 | nuclear receptor coactivator 7 | 2 | 2 | ||||||||
MIRT545156 | GABRG1 | gamma-aminobutyric acid type A receptor gamma1 subunit | 2 | 2 | ||||||||
MIRT545848 | ZNF264 | zinc finger protein 264 | 2 | 4 | ||||||||
MIRT546064 | VEZF1 | vascular endothelial zinc finger 1 | 2 | 2 | ||||||||
MIRT546481 | SLC16A14 | solute carrier family 16 member 14 | 2 | 4 | ||||||||
MIRT551835 | AASDHPPT | aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | 2 | 2 | ||||||||
MIRT551901 | ACP1 | acid phosphatase 1, soluble | 2 | 2 | ||||||||
MIRT552490 | ZNF136 | zinc finger protein 136 | 2 | 2 | ||||||||
MIRT554206 | SLC35A5 | solute carrier family 35 member A5 | 2 | 2 | ||||||||
MIRT554295 | SIPA1L2 | signal induced proliferation associated 1 like 2 | 2 | 2 | ||||||||
MIRT555765 | PCTP | phosphatidylcholine transfer protein | 2 | 2 | ||||||||
MIRT558315 | DSG2 | desmoglein 2 | 2 | 2 | ||||||||
MIRT563147 | NOLC1 | nucleolar and coiled-body phosphoprotein 1 | 2 | 2 | ||||||||
MIRT566464 | PGGT1B | protein geranylgeranyltransferase type I subunit beta | 2 | 2 | ||||||||
MIRT567322 | HMGB2 | high mobility group box 2 | 2 | 2 | ||||||||
MIRT567738 | DLX2 | distal-less homeobox 2 | 2 | 2 | ||||||||
MIRT567892 | CSTF2 | cleavage stimulation factor subunit 2 | 2 | 2 | ||||||||
MIRT570087 | KANSL1L | KAT8 regulatory NSL complex subunit 1 like | 2 | 2 | ||||||||
MIRT571136 | TTC33 | tetratricopeptide repeat domain 33 | 2 | 2 | ||||||||
MIRT573534 | MDM2 | MDM2 proto-oncogene | 2 | 2 | ||||||||
MIRT574465 | RPS16 | ribosomal protein S16 | 2 | 2 | ||||||||
MIRT574998 | Phka1 | phosphorylase kinase alpha 1 | 2 | 3 | ||||||||
MIRT610202 | CD99 | CD99 molecule (Xg blood group) | 2 | 4 | ||||||||
MIRT612926 | GPRIN3 | GPRIN family member 3 | 2 | 2 | ||||||||
MIRT615027 | DUSP6 | dual specificity phosphatase 6 | 2 | 2 | ||||||||
MIRT617200 | GREM1 | gremlin 1, DAN family BMP antagonist | 2 | 2 | ||||||||
MIRT628720 | ZNF585A | zinc finger protein 585A | 2 | 2 | ||||||||
MIRT641491 | POLA2 | DNA polymerase alpha 2, accessory subunit | 2 | 2 | ||||||||
MIRT641663 | PAPOLG | poly(A) polymerase gamma | 2 | 2 | ||||||||
MIRT642216 | RUVBL2 | RuvB like AAA ATPase 2 | 2 | 2 | ||||||||
MIRT654589 | PURA | purine rich element binding protein A | 2 | 2 | ||||||||
MIRT656136 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT656899 | KIAA2018 | upstream transcription factor family member 3 | 2 | 2 | ||||||||
MIRT660136 | BRPF3 | bromodomain and PHD finger containing 3 | 2 | 2 | ||||||||
MIRT660861 | AFAP1 | actin filament associated protein 1 | 2 | 2 | ||||||||
MIRT676849 | PHKA1 | phosphorylase kinase regulatory subunit alpha 1 | 2 | 3 | ||||||||
MIRT681479 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT682259 | RS1 | retinoschisin 1 | 2 | 2 | ||||||||
MIRT685602 | MYOM2 | myomesin 2 | 2 | 2 | ||||||||
MIRT686943 | SFT2D3 | SFT2 domain containing 3 | 2 | 2 | ||||||||
MIRT694302 | COPB2 | coatomer protein complex subunit beta 2 | 2 | 2 | ||||||||
MIRT694407 | ALDH1A3 | aldehyde dehydrogenase 1 family member A3 | 2 | 2 | ||||||||
MIRT697280 | ZNF800 | zinc finger protein 800 | 2 | 2 | ||||||||
MIRT698414 | TM4SF1 | transmembrane 4 L six family member 1 | 2 | 2 | ||||||||
MIRT698989 | SPAG9 | sperm associated antigen 9 | 2 | 2 | ||||||||
MIRT699766 | SEMA4D | semaphorin 4D | 2 | 2 | ||||||||
MIRT699928 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT702113 | MBNL1 | muscleblind like splicing regulator 1 | 2 | 2 | ||||||||
MIRT702373 | KLF10 | Kruppel like factor 10 | 2 | 2 | ||||||||
MIRT702646 | ITGA3 | integrin subunit alpha 3 | 2 | 2 | ||||||||
MIRT705713 | ANAPC16 | anaphase promoting complex subunit 16 | 2 | 2 | ||||||||
MIRT717925 | ZNF546 | zinc finger protein 546 | 2 | 2 | ||||||||
MIRT720839 | C1orf52 | chromosome 1 open reading frame 52 | 2 | 2 | ||||||||
MIRT725033 | NDUFAF7 | NADH:ubiquinone oxidoreductase complex assembly factor 7 | 2 | 2 | ||||||||
MIRT731448 | APOBEC3A | apolipoprotein B mRNA editing enzyme catalytic subunit 3A | 1 | 1 | ||||||||
MIRT733217 | CCNG1 | cyclin G1 | 2 | 0 | ||||||||
MIRT734887 | LIN28B | lin-28 homolog B | 1 | 0 | ||||||||
MIRT735276 | HMGA2 | high mobility group AT-hook 2 | 2 | 0 | ||||||||
MIRT735727 | SYNCRIP | synaptotagmin binding cytoplasmic RNA interacting protein | 3 | 0 | ||||||||
MIRT736087 | RCVRN | recoverin | 1 | 0 | ||||||||
MIRT736088 | RHO | rhodopsin | 1 | 0 | ||||||||
MIRT736103 | TLR7 | toll like receptor 7 | 1 | 0 | ||||||||
MIRT736607 | TPO | thyroid peroxidase | 2 | 0 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|